Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Betting platforms like Kalshi and Polymarket are facing criticism for allowing users to wager on clinical trial outcomes, with some researchers arguing this could lead to insider trading and disrupt the drug development process. Despite these concerns, the platforms claim they offer valuable insights and information to patients. This debate highlights the tension between innovation in healthcare data sharing and the potential risks of influencing scientific processes. The implications could shape future regulations around clinical trial transparency and data usage.